Abstract
Different factors have contributed to make Lung Squamous carcinoma (LUSC) a less-studied type of NSCLC as compared to Lung Adenocarcinoma (LUAD). In general, LUSC has larger genetic and phenotypic heterogeneity than LUAD and, in most cases, there are not evident oncogenic driver mutations, which is a major hurdle to understand its biology. The number of suitable mouse models and cell lines for the study of immunotherapy in lung squamous cell carcinoma (LUSC) is still insufficient. Here we present two syngeneic cell lines which may contribute to the armamentarium of LUSC researchers, especially in the fields of immunotherapy and metastasis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
